GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gelesis Holdings Inc (OTCPK:GLSHQ) » Definitions » EV-to-FCF

Gelesis Holdings (Gelesis Holdings) EV-to-FCF : -1.08 (As of May. 05, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Gelesis Holdings EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Gelesis Holdings's Enterprise Value is $54.12 Mil. Gelesis Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was $-50.33 Mil. Therefore, Gelesis Holdings's EV-to-FCF for today is -1.08.

The historical rank and industry rank for Gelesis Holdings's EV-to-FCF or its related term are showing as below:

GLSHQ' s EV-to-FCF Range Over the Past 10 Years
Min: -6.93   Med: -1.33   Max: -0.61
Current: -1.08

During the past 2 years, the highest EV-to-FCF of Gelesis Holdings was -0.61. The lowest was -6.93. And the median was -1.33.

GLSHQ's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 4.57 vs GLSHQ: -1.08

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), Gelesis Holdings's stock price is $0.0021. Gelesis Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.700. Therefore, Gelesis Holdings's PE Ratio for today is At Loss.


Gelesis Holdings EV-to-FCF Historical Data

The historical data trend for Gelesis Holdings's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gelesis Holdings EV-to-FCF Chart

Gelesis Holdings Annual Data
Trend Dec21 Dec22
EV-to-FCF
- -1.02

Gelesis Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.78 -1.23 -1.02 -1.41 -1.38

Competitive Comparison of Gelesis Holdings's EV-to-FCF

For the Biotechnology subindustry, Gelesis Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gelesis Holdings's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gelesis Holdings's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Gelesis Holdings's EV-to-FCF falls into.



Gelesis Holdings EV-to-FCF Calculation

Gelesis Holdings's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=54.120/-50.33
=-1.08

Gelesis Holdings's current Enterprise Value is $54.12 Mil.
Gelesis Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-50.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gelesis Holdings  (OTCPK:GLSHQ) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Gelesis Holdings's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0021/-0.700
=At Loss

Gelesis Holdings's share price for today is $0.0021.
Gelesis Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.700.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Gelesis Holdings EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Gelesis Holdings's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Gelesis Holdings (Gelesis Holdings) Business Description

Traded in Other Exchanges
N/A
Address
501 Boylston Street, Suite 6102, Boston, MA, USA, 02116
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
Executives
Raju S Kucherlapati director 77 LOUIS PASTEUR AVENUE, BOSTON MA 02115
Bomsmaster Llc 10 percent owner 195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510
Paul R. Fonteyne director C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Hpso Spv Ltd 10 percent owner SARNIA HOUSE, LE TRUCHOT, ST PETER PORT Y7 GY1 4NA
Alessandro Sannino officer: Lead Project Scientist C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Dominic Perks director GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON NY 02116
David A. Pass officer: Chief Op. & Comm. Officer GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON MA 02116
Elaine Chiquette officer: Chief Scientific Officer C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Jane Wildman director C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Harry L. Leider officer: Chief Medical Officer C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Clayton Christopher director 2407 S. CONGRESS AVE, SUITE E103, AUSTIN TX 78704
Health Plc Puretech 10 percent owner 6 TIDE STREET, SUITE 400, BOSTON MA 02210
Ssd2, Llc 10 percent owner 142 TEMPLE STREET, SUITE 206, NEW HAVEN CT 06511
Yishai Zohar director, officer: President & CEO C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Elon Boms 10 percent owner C/O THIMBLE POINT ACQUISITION CORP., 195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510

Gelesis Holdings (Gelesis Holdings) Headlines

From GuruFocus

Gelesis to Report Full Year 2021 Financial Results on March 24, 2022

By Business Wire Business Wire 03-17-2022